Definition: In this task, you are given a text of many news articles seperated by special token "|||||". Your task is to summarize them.
Input: One in seven people worldwide experience migraines, among them 37 million Americans — as many as 20 percent of women, and 10 percent of men. 
  
 About 2 percent of the global population copes with chronic migraines. By some estimates, migraine is the third most common disease in the world, and it ranks among the top ten causes of disability. 
  
 It is not just a headache: A migraine often is accompanied by disabling symptoms like nausea and vomiting, difficulty speaking, and an aversion to light and noise. The headache can be throbbing and last for hours or days. 
  
 The new medicines are intended for the estimated 2.8 million Americans who have a migraine many times each month. Treating these people has been challenging, doctors say. 
  
 Patients often try the currently available treatments one after another, in varying combinations. Drug side effects are frequent and include mental fogginess, sedation, weight gain, sexual dysfunction and dry mouth leading to cavities. 
  
 Some patients find the side effects worse than the migraines. Eighty-five percent of migraine patients stop taking the drugs within a year. 
  
 For a draft review of migraine drugs, the nonprofit Institute for Clinical and Economic Review surveyed patients with frequent migraines. Many said they did not make plans or commitments — even staying out of the work force — because they never knew when they would get a migraine that could disable them for hours or days. ||||| (Corrects to $10,000 a year instead of $10,000 a month, paragraph 3) 
  
 By Deena Beasley 
  
 May 17 (Reuters) - Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults. 
  
 The drug, Aimovig, which is given monthly by self-injection, will have a list price of $6,900 a year, or $575 a month, the company said. Any discounts or rebates will depend on negotiations with health plans, Amgen spokeswoman Kristen Davis said. 
  
 Some Wall Street analysts had expected a price as high as $10,000 a year. 
  
 Amgen’s pricing strategy “appears to play into (an) appropriate framework of lower gross pricing,” Jefferies analyst Michael Yee said in a research note. 
  
 Express Scripts, the largest U.S. manager of prescription benefits, has called for Amgen to reconsider its strategy of setting a high list price for new drugs and then lowering the cost for health plans through hefty rebates. 
  
 Yee said Aimovig’s net price could fall to around $5,000 to $6,000 a year after rebates and discounts. 
  
 U.S. President Donald Trump last week blasted drugmakers and healthcare “middlemen” for making prescription medicines unaffordable for Americans as the administration said it would act to boost competition between pharmaceutical companies and test ways to pay for drugs based on their effectiveness. 
  
 The administration said longer-term priorities include restricting use of rebates, creating incentives for drugmakers to lower list prices, and investigating tools to address foreign government practices that it said could be harming innovation and driving up U.S. prices. 
  
 Aimovig is the first in a new class of treatments designed to prevent migraine by interfering with calcitonin gene-related peptide (CGRP), which is involved in the processes that kick off the severe headaches, such as dilation of blood vessels in the brain. 
  
 Companies including Teva Pharmaceutical Industries , Eli Lilly & Co and Alder Biopharmaceuticals Inc are developing similar treatments. 
  
 Preventive medications may be an option for around eight million Americans suffering from migraines, Amgen said. 
  
 In three separate pivotal trials, involving patients with chronic or episodic migraines, patients given Aimovig experienced an average of one to 2.5 fewer migraine days a month than those treated with a placebo, the FDA said. 
  
 The most common side effects reported by patients in the trials were injection site reactions and constipation. 
  
 Current migraines treatments are mostly repurposed generic drugs including anti-depressants and hypertension medicines. Allergan’s anti-wrinkle injection Botox is approved for patients suffering from 15 or more migraine headaches a month. 
  
 Analysts, on average, have forecast annual Aimovig sales of nearly $1 billion by 2022, according to Thomson Reuters I/B/E/S. 
  
 Express Scripts has also suggested that Aimovig prescriptions be at least partially refunded if the drug fails to work, since many patients in the clinical trials did not have a significant response to the treatment. 
  
 Amgen, which will market Aimovig in partnership with Novartis, said the drug’s price “reflects the value it brings to patients and society.” The company said it will pay most out-of-pocket costs for eligible patients with commercial insurance. (Reporting by Deena Beasley; Editing by Leslie Adler and Grant McCool) ||||| Migraine is a common chronic condition characterized by recurrent attacks of severe headache with associated symptoms such as light and sound sensitivity, nausea, vomiting, and focal neurological disturbances. In 2016, migraine affected an estimated 1.04 billion people worldwide.1 Migraine prevalence and disease activity are highest among women during their childbearing years.2 Approximately 14% of people with migraine experience 5 or more attacks per month.3 For many patients, migraine episodes are debilitating, and overall, 25% of people with migraine report that they have missed a day of work or school because of migraine in the previous 3 months.3 ||||| Breaking News Emails Get breaking news alerts and special reports. The news and stories that matter, delivered weekday mornings. 
  
 / Updated By Shamard Charles, MD 
  
 The Food and Drug Administration approved a new migraine drug on Thursday. 
  
 Aimovig, known generically as erenumab, is the first drug in a new class of headache medicines. It's been shown to stop migraine headaches before they start. 
  
 The drug would be approved for patients who have tried other drugs and found no relief. In studies, it did not entirely prevent migraines, but reduced their frequency. 
  
 “Aimovig provides patients with a novel option for reducing the number of days with migraine,” said Dr. Eric Bastings, deputy director of the FDA's neurology products division. 
  
 “We need new treatments for this painful and often debilitating condition.” 
  
 FDA's approval means the drug may soon be available under prescription. It should also be paid for by health insurance. 
  
 The drug's maker, Amgen, said U.S. list price is for the once monthly self-injection treatment will be $575 per month or $6,900 annually. 
  
 “The price of Aimovig reflects the value it brings to patients and society, including the financial impact on sufferers, caregivers and employers, while also factoring in critical issues such as patient affordability, and fair and timely access,” Amgen said in a statement. 
  
 Erenumab the first in a new class of drugs that block calcitonin gene-related peptide (CGRP), a molecule that transmits migraine pain signals during an attack. It's a human monoclonal antibody -- a targeted immune system protein. 
  
 It's formulated as an injection to provide long-lasting protection. 
  
 More than 39 million Americans suffer from migraine attacks, according to the Migraine Research Foundation. Of these, about 4 million have chronic migraine and suffer headaches for 10 to 14 days a month. 
  
 While some people are helped by low cost, over-the-counter drugs such as ibuprofen, others need prescription medications, such as sumatriptan and ergotamine, which constrict the blood vessels in the brain and can cause dizziness or nausea. Botox injections are also used to help ease migraines in some people. 
  
 But a large percentage of sufferers are not helped by anything. 
  
 "This is the first-ever mechanism specific migraine drug designed for prevention," said Dr. Peter Goadsby, professor of neurology at Kings College London and the University of California, San Francisco, who is a lead researcher on the drug. "This will change migraine treatment for those who don’t respond to conventional treatments." 
  
 Goadsby's team found that the drug reduced the average number of monthly migraine headaches by more than 50 percent for nearly half of study participants. After three months, patients treated with the human antibody were nearly three times more likely to have reduced their migraine days by 50 percent or more than those treated with placebo. 
  
 Participants of the study also had a greater average reduction in the number of days with headaches and the number of days they needed to take drugs to stop the migraines. 
  
 No patients taking erenumab stopped treatment due to adverse side effects, but the scientists noted that more research will needed to investigate if the benefits continue. 
  
 Malden, Massachusetts native Denise Desjardins, 58, with niece Madeline Salvitella suffered from migraine headaches for over 10 years, but found great relief after taking erenumab, a fully human monoclonal antibody drug that is showing great promise in migraine prevention. Denise Dejardins 
  
 Malden, Massachusetts native Denise Desjardins, 58, coped with migraine headaches for more than 10 years, particularly around her menstrual cycle. 
  
 “I would land in bed for two to three days, four to five times a year,” said Desjardins. “These were in-your-bed, no-matter-what headaches.” 
  
 Her migraines became a daily misery after a bilateral mastectomy following a diagnosis of breast cancer. She was put on Imitrex, a popular migraine drug that helps to quiet overactive pain nerves in the brain, but it didn't help. 
  
 For about four years, Desjardins has been taking an erenumab injection once a month, without any side effects, as part of the study. 
  
 "I don't even think I get migraines anymore," said Desjardins. 
  
 “I think having a treatment that is specifically invented to treat a disease that affects millions of people, makes this a big game changer,” said Dr. Dario Zagar, president of Associated Neurologists of Southern Connecticut. 
  
 Because other migraine medications were not developed for headache, their side effects limited how well patients could tolerate them. 
  
 “I think someone who gets migraines, will tell you they would do just about anything to reduce how frequently they're getting them — and if you told someone who was getting migraines two or three times a week that they would only get one (a week) or possibly none at all — they would be very happy,” said Zagar. |||||
Output:
"Progress, but not a panacea." So proclaims an editorial in journal JAMA on Aimovig, a first-of-its-kind drug purported to prevent chronic migraines without many side effects that was on Thursday approved by the FDA. The drug from Amgen and Novartis, and similar ones in their final stages, "shake the ground under our feet. They will change the way we treat migraine," a neurologist tells the New York Times. "The drugs will have a huge impact," another adds. At $575 per unit, the self-administered monthly injection known generically as erenumab doesn't eliminate migraines, but it can halve their frequency and cut their intensity by blocking the protein fragment responsible. None of the patients in the trials bowed out due to side effects; constipation and reactions around the injection site were most common, per Reuters. Aimovig users experienced up to 2.5 fewer migraine days per month on average than placebo recipients in three separate trials, according to the FDA. Now forced to rely on drugs designed to treat other issues—Botox is prescribed for some—the roughly 3 million Americans who suffer chronic migraines could get their hands on the drug within a week, per the Times. Its price tag "reflects the value it brings to patients … while also factoring in critical issues such as patient affordability," Amgen says, per NBC News. Reuters reports the $6,900 annual cost is below the $10,000 estimated by some analysts. (Migraines may be linked to mouth bacteria.)